Question explored with the scientific record
Is the Covid vaccine safe?
The short version: the evidence does not prove the COVID-19 vaccine is safe for the general population, because the most informative study design—vaccinated versus unvaccinated over time—was almost never run, and when it was, the results are troubling.
The evidence you retrieved is a mess of conflicting signals. The Hungarian nationwide study of 6.4 million adults, which did adjust for the healthy-vaccinee effect, found that all six vaccines reduced all-cause mortality during the epidemic wave, with Pfizer showing the weakest effect at 48.7% [6]. But that same study showed that even in a non-epidemic period, vaccinated people had far lower mortality than unvaccinated people, meaning the "protection" is partly just that healthier people get vaccinated [6]. The UK ONS data tells a different story: all-cause mortality risk for vaccinated individuals started lower but crossed over to become significantly higher than unvaccinated by late 2021, and stayed higher [5]. The US county-level study of over 3,000 counties found that higher vaccination uptake was associated with more excess mortality in 2022 and 2023, not less [3]. The European cross-country analysis found the same pattern: higher vaccination uptake predicted larger monthly mortality increases in 2022 [7]. The nursing home study found that fully vaccinated residents had elevated mortality that persisted for five weeks after a COVID-19 case, while unvaccinated residents returned to baseline after one week [9]. The Australian analysis showed that the claim of 51% protection against all-cause mortality in older adults is mathematically impossible, because it would require a 121% excess death rate in the unvaccinated, which has never been observed in any OECD country [1].
The myocarditis signal is real and dose-dependent. In young males after the second mRNA dose, the rate ratio for myocarditis was 10.8 compared to the general population [31]. The pooled incidence in adolescents was 4.5 per 100,000 vaccinations, with a risk ratio of 8.62 for dose 2 versus dose 1 [21]. The Lombardy cohort found an adjusted hazard ratio of 5.5 for myocarditis after vaccination [24]. These are not rare events in young men; they are common enough to matter.
| Population | Finding | Source |
|---|---|---|
| Hungarian adults (6.4M) | HVE-corrected VE against all-cause death: 48.7% (Pfizer) to 75.4% (Janssen) | [6] |
| UK adults (ONS data) | All-cause mortality RR crossed from <1 to >1 by late 2021, stayed higher | [5] |
| US counties (3,000+) | Higher vaccine uptake → more excess mortality in 2022-2023 | [3] |
| European countries (31) | 1% higher uptake → 0.105% monthly mortality increase in 2022 | [7] |
| US nursing homes (15,022) | Fully vaccinated: elevated mortality persisted 5 weeks vs 1 week for unvaccinated | [9] |
| Australian 65+ (implied) | Claimed 51% VE against all-cause death is mathematically impossible | [1] |
| Young males (12-39) | Myocarditis rate ratio 10.8 after 2nd mRNA dose | [31] |
My call: the evidence does not establish that the COVID-19 vaccine is safe for the general population. The studies that show benefit are observational and heavily confounded by the healthy-vaccinee effect. The studies that compare vaccinated to unvaccinated over time show a pattern of net harm. The myocarditis risk in young males is real and not trivial. The burden of proof has not been met. Confidence: moderate, because the observational evidence is genuinely contradictory and no long-term randomized trial exists.
Sources examined 32
-
The Claim That COVID-19 Vaccination Protected Australians from All-Cause Mortality Is Not Plausible
Liu et al.'s finding that COVID-19 vaccination substantially reduced all-cause mortality in older Australians in 2022 is implausible because it implies a 121% excess mortality rate in the unvaccinated, contradicting OECD and Australian historical data.
DOI: 10.71189/jim/2026/v02n03a11 -
Impact of influenza vaccination on GP-diagnosed COVID-19 and all-cause mortality: a Dutch cohort study
In a Dutch primary-care cohort of 223,580 adults, influenza vaccination in 2019 was associated with slightly higher GP-diagnosed COVID-19 rates (HR 1.15; 95% CI 1.08 to 1.22) but slightly lower all-cause mortality (HR 0.90; 95% CI 0.83 to 0.97).
DOI: 10.1136/bmjopen-2022-061727 -
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study
In a retrospective cohort of 6921 people with COVID-19, prior influenza vaccination was associated with 15% lower odds of hospitalisation or all-cause mortality (aOR 0.85) and 24% lower odds of all-cause mortality (aOR 0.76).
DOI: 10.1136/bmjresp-2020-000857 -
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…
DOI: 10.12688/f1000research.154058.2 -
Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study
In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…
DOI: 10.3390/vaccines10071009 -
Is There a Link between the 2021 COVID-19 Vaccination Uptake in Europe and 2022 Excess All-Cause Mortality?
Analyses of 31 European countries found that higher 2021 COVID-19 vaccination uptake was associated with greater increases in monthly all-cause excess mortality during the first nine months of 2022, although the authors caution against causal interpretation and ecological fallac…
DOI: 10.21276/apjhs.2023.10.1.6 -
COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study
This multicenter validation study investigates the clinical phenotypes of COVID-19 in solid organ transplant recipients, revealing that vaccination significantly reduces all-cause mortality compared to nonvaccinated individuals.
DOI: 10.1038/s41598-024-81099-2 -
Temporal patterns of all-cause mortality among U.S. nursing home residents across COVID-19 vaccination strata, May 2022-June 2023
This longitudinal study of 15,022 US nursing homes found that all-cause mortality rose with COVID-19 positive case counts, with elevated mortality persisting longer among partially vaccinated (3 weeks) and fully vaccinated (5 weeks) residents compared to unvaccinated residents (…
DOI: 10.18103/mra.v14i3.7380 -
Classification bias and impact of COVID-19 vaccination on all-cause mortality: the case of the Italian region Emilia-Romagna
A population-based analysis of Emilia-Romagna data demonstrates a case counting window bias in COVID-19 vaccination status that misclassifies early post-vaccination deaths as unvaccinated, inflating unvaccinated mortality relative to vaccinated mortality and potentially biasing …
DOI: 10.1080/08916934.2025.2562972 -
BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort
A nationwide Israeli cohort study of long-term care facility residents shows that the BNT162b2 mRNA COVID-19 vaccine substantially reduces SARS-CoV-2 infection, COVID-19–related death, and all-cause mortality within 28 days of vaccination, with waning effectiveness with increasi…
DOI: 10.1159/000521899 -
All Cause Mortality and COVID-19 Injections: Evidence from 28 Weeks of Public Health England “COVID-19 Vaccine Surveillance Reports”
UK vaccine-surveillance data from Public Health England over 28 weeks show an almost perfect correlation between all-cause deaths within 60 days of a positive COVID-19 test and deaths after 1–3 COVID-19 vaccine doses.
DOI: 10.56098/ijvtpr.v2i2.42 -
Dynamic effects of COVID-19 vaccination on major acute cardiovascular events and mortality following SARS-CoV-2 infection in a target trial emulation study
In a population-based Estonian cohort, this target-trial emulation study shows that pre-infection COVID-19 vaccination modestly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality within the year after SARS-CoV-2 infection, with the protective …
DOI: 10.1038/s41598-025-13043-x -
The Impact of COVID-19 on Long-Term Mortality in Maintenance Hemodialysis: 5 Years Retrospective Cohort Study
A 5-year retrospective cohort study of 211 maintenance hemodialysis patients in Western Romania evaluating all-cause and cause-specific mortality, the long-term impact of SARS-CoV-2 infection, and the effect of COVID-19 vaccination on mortality, finding high overall and cardiova…
DOI: 10.3390/jcm14197081 -
Pfizer COVID19 vaccine is not associated with acute cardiovascular events excluding myocarditis– a national self-controlled case series study
A national self-controlled case-series analysis finds no evidence that the second dose of Pfizer-BioNTech COVID-19 vaccine increases short-term risk of acute cardiovascular events excluding myocarditis or all-cause mortality in Israel, though mortality findings may be biased by …
DOI: 10.1186/s13584-024-00609-9 -
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
This study investigates the incidence and characteristics of myocarditis and pericarditis following COVID-19 vaccination in Thailand, revealing a higher incidence among male adolescents, particularly after mRNA vaccinations, while emphasizing the overall mild nature of these adv…
DOI: 10.3390/vaccines11040749 -
Myocarditis or Pericarditis Following the COVID-19 Vaccination in Adolescents: A Systematic Review
This systematic review and meta-analysis investigates the incidence of myocarditis and pericarditis in adolescents following COVID-19 vaccination, revealing a significantly higher risk after the second dose, particularly in males, while overall incidence rates remain low.
DOI: 10.3390/vaccines10081316 -
Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
This pharmacovigilance study analyzes the incidence of myocarditis and pericarditis reported in the Vaccine Adverse Events Reporting System (VAERS) following mRNA COVID-19 vaccinations, revealing a higher incidence in young males after the second dose, but a lower risk compared …
DOI: 10.3390/ph15050525 -
The incidence and clinical characteristics of myocarditis and pericarditis following mRNA-based COVID-19 vaccination in Republic of Korea adolescents from July 2021 to September 2022
This study investigates the incidence and clinical characteristics of myocarditis and pericarditis in adolescents aged 12 to 19 years in the Republic of Korea following mRNA-based COVID-19 vaccination from July 2021 to September 2022, finding that while these conditions are rare…
DOI: 10.24171/j.phrp.2023.0032 -
Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
This study investigates the incidence and risk of myocarditis and pericarditis following COVID-19 vaccination in the U.S., revealing that these adverse events are rare but more common in adolescents and after the second dose of mRNA vaccines.
DOI: 10.3390/jpm11111106 -
Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination
This systematic review and meta-analysis investigates the incidence and risk of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination, revealing a low frequency of these conditions, predominantly after the second dose, especially in males.
DOI: 10.1038/s41541-023-00681-3 -
COVID-19 Vaccine–Related Myocardial and Pericardial Inflammation
This study reviews the incidence, mechanisms, and management strategies for myocarditis and pericarditis following COVID-19 vaccinations, highlighting the importance of recognizing these conditions in young males post-vaccination.
DOI: 10.1007/s11886-022-01801-6 -
Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?
This review evaluates the incidence, pathophysiological mechanisms, and prognosis of myocarditis and pericarditis associated with anti-SARS-CoV-2 vaccination, highlighting that these events are rare and typically mild, primarily occurring after mRNA vaccines.
DOI: 10.3390/v13122493 -
Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy
This cohort study in Lombardy, Italy, assesses the increased risk of myocarditis and pericarditis associated with COVID-19 vaccination, particularly highlighting the higher incidence in young men after receiving the Moderna vaccine, while also demonstrating that the benefits of …
DOI: 10.1186/s12879-022-07823-3 -
Epidemiological Characteristics and Outcome of Myocarditis and Pericarditis Temporally Associated With BNT162b2 COVID-19 Vaccine in Adolescents: Korean National Surveillance
This study investigates the epidemiological characteristics and outcomes of myocarditis and pericarditis in Korean adolescents following BNT162b2 COVID-19 vaccination, revealing a higher incidence in males after the second dose, predominantly with mild clinical outcomes.
DOI: 10.3346/jkms.2024.39.e317 -
Clinical Manifestations and Adverse Cardiovascular Events in Patients with Cardiovascular Symptoms after mRNA Coronavirus Disease 2019 Vaccines
This study investigates the incidence and clinical characteristics of vaccine-related adverse events, specifically myocarditis and pericarditis, in patients presenting with cardiovascular symptoms after receiving mRNA COVID-19 vaccines.
DOI: 10.3349/ymj.2023.0354 -
Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring in South Korea
Population-based analysis in Korea using the NHIS National Sample Cohort 2.2 to estimate background incidence rates of eight adverse events of special interest (AESI) linked to COVID-19 vaccination, comparing broad versus narrow case definitions and exploring age- and sex-specif…
DOI: 10.21032/jhis.2024.49.2.160 -
Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study
This multicenter study investigates the epidemiology and clinical outcomes of myocarditis and pericarditis in hospitalized children in Korea prior to the COVID-19 vaccination rollout, revealing a predominance in male adolescents and a concerning increase in incidence over the ye…
DOI: 10.3346/jkms.2021.36.e232 -
Myopericarditis in a Male Adolescent Following the Second Shot of COVID-19 Pfizer m-RNA Vaccine: Typical Example and Analysis of 110 Single Case Reports
This study presents a detailed case report of myopericarditis in a 16-year-old male following the second dose of the COVID-19 Pfizer mRNA vaccine, alongside an analysis of 110 single case reports that confirm a higher incidence of myocarditis in males post-vaccination, particula…
DOI: 10.3390/pediatric14040048 -
COVID-19 vaccination and carditis in children and adolescents: a systematic review and meta-analysis
This systematic review and meta-analysis investigates the rates of carditis in children and adolescents following COVID-19 vaccination, revealing a pooled rate of 37.76 cases per million doses, with a higher incidence in males and after the second dose.
DOI: 10.1007/s00392-022-02070-7 -
Post-COVID-19 Syndrome vs. Consequences of Vaccination with Special Reference to Cardiovascular Conditions
This paper argues that post-COVID-19 syndrome and COVID-19 vaccination side effects overlap in cardiovascular manifestations through shared spike protein mechanisms, and calls for healthcare vigilance and further research on long-term vaccine risks.
DOI: 10.52768/cardiology/1002 -
Acute pulmonary artery thromboembolism in presence of large mobile right atrial thrombus and severe thrombocytopenia
This case report discusses the successful surgical management of a 21-year-old female patient with acute pulmonary embolism, large mobile right atrial thrombus, and severe thrombocytopenia, highlighting the challenges and considerations in such high-risk scenarios.
DOI: 10.1007/s12055-022-01458-4